The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
The campaign builds on the three-year partnership unveiled earlier this season
Board approves five-year appointment, subject to shareholder nod through postal ballot
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Company to launch product after the expiry of semaglutide patent in India
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Subscribe To Our Newsletter & Stay Updated
